New Delhi, June 3 -- Biocon Pharma Limited, a biopharmaceutical firm, on Tuesday said that drug regulator, Drugs Controller General of India under the CDSCO (Central Drugs Standard Control Organisation) has given nod to its liraglutide drug for Indian market.
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise.
Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, termed the approval for liraglutide, as a step forward in expanding access of this product to patients suffering from diabetes.
"The approval enables us to address a critical ...